Sunshine Act vs. Anti-Kickback Statute: What Life Science Companies Need to Know
Author
May Khan leads the Compliance Services team at Vector Health, a SaaS company focused on life sciences compliance. Her experience includes global transparency reporting, Sunshine Act strategy, and HCP risk monitoring. At Vector, she coordinates cross-functional teams focused on data integrity, customer service, and regulatory alignment.
Vector Health Compliance
Your Leading Partner in Global Sunshine Compliance
Here is a clear breakdown of what each law does, how they overlap, and what your compliance programme needs to account for.
What Is the Anti-Kickback Statute?
The Anti-Kickback Statute (AKS) is a federal criminal law that prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or reward referrals of items or services reimbursable by federal healthcare programmes such as Medicare and Medicaid. In practice, this means pharmaceutical and medical device companies cannot provide improper financial incentives, such as excessive consulting fees, lavish entertainment, or inflated travel reimbursements, to healthcare professionals or other referral sources in a way that could induce or reward Federal healthcare program business.
Violations of the AKS can result in criminal prosecution, civil monetary penalties, and exclusion from federal healthcare programmes. The intent behind the payment matters: if a transfer of value is structured in a way that could be seen as an inducement for referrals, it may implicate AKS risk even if the arrangement is not framed as a direct referral payment.
What Is the Sunshine Act?
The Physician Payments Sunshine Act is implemented through CMS’s Open Payments program and functions as a federal transparency reporting framework. Unlike the AKS, it does not prohibit payments; it requires that they be disclosed. Under Open Payments, reporting entities — including applicable manufacturers and applicable group purchasing organizations (GPOs) — must report certain payments or other transfers of value made to covered recipients, including physicians, advanced practice providers/non-physician practitioners, and teaching hospitals, unless an exclusion applies.
Reportable transfers of value may include consulting fees, speaking engagements, meals, travel, research funding, and other categories required to be reported under Open Payments. The data is then published through the Open Payments programme, where it can be reviewed by patients, journalists, researchers, regulators, and the public.
How Do They Interact?
Think of the two laws as working on different layers. The AKS is a legality and risk-assessment layer: it helps determine whether a financial relationship could be viewed as improper remuneration connected to Federal healthcare program business. The Sunshine Act is the transparency layer: it requires that permissible relationships with HCPs be disclosed to the public and to regulators.
A payment may be properly reported under the Sunshine Act and still present Anti-Kickback Statute risk if the underlying arrangement involves improper remuneration or intent. Conversely, failing to report a legitimate payment under the Sunshine Act does not make that payment illegal under the AKS; it simply creates a separate disclosure violation.
Common Misconceptions
- “We reported it to CMS, so we are covered.” — Reporting a payment does not make it legal. Disclosure and legality are separate questions.
- “We do not pay physicians for referrals, so the AKS does not apply to us.” — The AKS is broader than direct referral payments. Financial relationships that could induce or reward referrals, purchasing, ordering, recommending, or other Federal healthcare program business may fall within its scope.
- “The Sunshine Act only applies to large companies.” — Company size does not determine applicability. Covered entities that meet the statutory definition of an applicable manufacturer or reporting entity may have reporting obligations regardless of size.
Practical Implications for Life Science Companies
For pharmaceutical and medical device companies, particularly those entering or expanding in the US market, understanding both laws is essential before engaging with any HCP. Transfers of value involving healthcare professionals should be evaluated through both lenses: Is the arrangement legally permissible under applicable fraud and abuse laws, including the AKS where relevant? And if so, does it create a reporting obligation under the Sunshine Act?
For covered reporting entities, building robust internal policies, maintaining accurate records of reportable HCP interactions, and filing timely Open Payments reports are core elements of a defensible compliance programme. Together, these measures help organizations maintain transparency, support reporting accuracy, and strengthen their overall compliance framework.
This article is provided for informational purposes only and does not constitute legal advice. Companies should consult qualified legal counsel regarding their specific compliance obligations.
Here is a clear breakdown of what each law does, how they overlap, and what your compliance programme needs to account for.
What Is the Anti-Kickback Statute?
The Anti-Kickback Statute (AKS) is a federal criminal law that prohibits knowingly and willfully offering, paying, soliciting, or receiving remuneration to induce or reward referrals of items or services reimbursable by federal healthcare programmes such as Medicare and Medicaid. In practice, this means pharmaceutical and medical device companies cannot provide improper financial incentives, such as excessive consulting fees, lavish entertainment, or inflated travel reimbursements, to healthcare professionals or other referral sources in a way that could induce or reward Federal healthcare program business.
Violations of the AKS can result in criminal prosecution, civil monetary penalties, and exclusion from federal healthcare programmes. The intent behind the payment matters: if a transfer of value is structured in a way that could be seen as an inducement for referrals, it may implicate AKS risk even if the arrangement is not framed as a direct referral payment.
What Is the Sunshine Act?
The Physician Payments Sunshine Act is implemented through CMS’s Open Payments program and functions as a federal transparency reporting framework. Unlike the AKS, it does not prohibit payments; it requires that they be disclosed. Under Open Payments, reporting entities — including applicable manufacturers and applicable group purchasing organizations (GPOs) — must report certain payments or other transfers of value made to covered recipients, including physicians, advanced practice providers/non-physician practitioners, and teaching hospitals, unless an exclusion applies.
Reportable transfers of value may include consulting fees, speaking engagements, meals, travel, research funding, and other categories required to be reported under Open Payments. The data is then published through the Open Payments programme, where it can be reviewed by patients, journalists, researchers, regulators, and the public.
How Do They Interact?
Think of the two laws as working on different layers. The AKS is a legality and risk-assessment layer: it helps determine whether a financial relationship could be viewed as improper remuneration connected to Federal healthcare program business. The Sunshine Act is the transparency layer: it requires that permissible relationships with HCPs be disclosed to the public and to regulators.
A payment may be properly reported under the Sunshine Act and still present Anti-Kickback Statute risk if the underlying arrangement involves improper remuneration or intent. Conversely, failing to report a legitimate payment under the Sunshine Act does not make that payment illegal under the AKS; it simply creates a separate disclosure violation.
Common Misconceptions
- “We reported it to CMS, so we are covered.” — Reporting a payment does not make it legal. Disclosure and legality are separate questions.
- “We do not pay physicians for referrals, so the AKS does not apply to us.” — The AKS is broader than direct referral payments. Financial relationships that could induce or reward referrals, purchasing, ordering, recommending, or other Federal healthcare program business may fall within its scope.
- “The Sunshine Act only applies to large companies.” — Company size does not determine applicability. Covered entities that meet the statutory definition of an applicable manufacturer or reporting entity may have reporting obligations regardless of size.
Practical Implications for Life Science Companies
For pharmaceutical and medical device companies, particularly those entering or expanding in the US market, understanding both laws is essential before engaging with any HCP. Transfers of value involving healthcare professionals should be evaluated through both lenses: Is the arrangement legally permissible under applicable fraud and abuse laws, including the AKS where relevant? And if so, does it create a reporting obligation under the Sunshine Act?
For covered reporting entities, building robust internal policies, maintaining accurate records of reportable HCP interactions, and filing timely Open Payments reports are core elements of a defensible compliance programme. Together, these measures help organizations maintain transparency, support reporting accuracy, and strengthen their overall compliance framework.
This article is provided for informational purposes only and does not constitute legal advice. Companies should consult qualified legal counsel regarding their specific compliance obligations.
Author
May Khan leads the Compliance Services team at Vector Health, a SaaS company focused on life sciences compliance. Her experience includes global transparency reporting, Sunshine Act strategy, and HCP risk monitoring. At Vector, she coordinates cross-functional teams focused on data integrity, customer service, and regulatory alignment.
Vector Health Compliance
Your Leading Partner in Global Sunshine Compliance